We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: news

Large Phase 3 Trials Show No Cognitive Benefit with Iclepertin in Schizophrenia — What the CONNEX Programme Teaches Us About Treating CIAS

MedXY Editorial Team•Nov 30, 2025•news
clinical trialscognitive impairmentschizophrenia

Highlights

– The CONNEX programme (three identical phase 3 trials) found no significant improvement in cognition with 10 mg iclepertin versus placebo at 26 weeks (MCCB overall composite T-score adjusted mean difference 0.127; 95% CI -0.396 to 0.650; p=0.63).

– Iclepertin was well tolerated with on-treatment adverse event rates similar to placebo (66% vs 69%); no safety signal emerged.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Integrating Plasma p-tau217 and APOE Genotype to Predict Cognitive Decline Across Diverse PopulationsThis pooled analysis of seven multi-ethnic cohorts demonstrates the combined prognostic value of plasma phosphorylated tau 217 concentrations and APOE-ε4 genotype for predicting risk and timing of cognitive impairment, emphasizing biomarkerSep 13, 2026Satralizumab Demonstrates Promising Efficacy and Safety in Treating Thyroid Eye Disease: Insights from Phase 3 SatraGO-1 and SatraGO-2 TrialsPhase 3 trials show satralizumab significantly improves proptosis, inflammation, and diplopia in thyroid eye disease with a favorable safety profile, marking a new therapeutic option targeting the IL-6 receptor pathway.Sep 12, 2026Global Efficacy of Aficamten in Nonobstructive Hypertrophic Cardiomyopathy: Insights from ACACIA-HCM and Complementary TrialsAficamten, a cardiac myosin inhibitor, demonstrated significant improvements in symptoms, diastolic function, and biomarkers in nonobstructive hypertrophic cardiomyopathy across multiple trials, including the pivotal ACACIA-HCM study.Sep 6, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Defining and Achieving Disease Stability in COPD: Insights from Phase 3 Trials
This article explores disease stability as a key treatment target in COPD, analyzing major phase 3 trials that show stability predicts reduced exacerbations and mortality, supporting its use to guide therapy.
Sep 9, 2026
Navigating Drug-Induced Liver Injury in Clinical Trials: Insights and Updates from FDA ExpertsDrug-Induced Liver Injury (DILI) remains a pivotal challenge in drug development, with evolving drug modalities and clinical trial designs prompting updated regulatory perspectives from FDA specialists.Sep 7, 2026
Relapse Trajectories and Antipsychotic Discontinuation in Schizophrenia: Insights from a Meta-Analysis and Contemporary EvidenceThis review synthesizes a meta-analysis of relapse trajectories following paliperidone discontinuation with evidence on antipsychotic maintenance and discontinuation strategies, highlighting individualized risk stratification and clinical iAug 27, 2026